Telomir Pharmaceuticals (NASDAQ:TELO) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Telomir Pharmaceuticals (NASDAQ:TELO) from a sell rating to a hold rating in a research note published on Saturday.

Several other brokerages also recently weighed in on TELO. Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Thursday, January 22nd. Rodman & Renshaw initiated coverage on Telomir Pharmaceuticals in a research note on Tuesday, January 13th. They set a “buy” rating for the company. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold”.

Telomir Pharmaceuticals Trading Up 0.9%

NASDAQ TELO opened at $1.14 on Friday. The stock has a market cap of $39.19 million, a P/E ratio of -3.08 and a beta of -0.49. The company’s fifty day simple moving average is $1.30 and its 200-day simple moving average is $1.39. Telomir Pharmaceuticals has a 52 week low of $1.05 and a 52 week high of $5.40.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in shares of Telomir Pharmaceuticals in the 4th quarter valued at approximately $53,000. Geode Capital Management LLC boosted its holdings in Telomir Pharmaceuticals by 14.0% in the fourth quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock worth $297,000 after purchasing an additional 27,519 shares during the period. World Investment Advisors bought a new stake in Telomir Pharmaceuticals during the fourth quarter valued at $47,000. Raymond James Financial Inc. raised its holdings in shares of Telomir Pharmaceuticals by 4,101.9% during the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock worth $105,000 after purchasing an additional 73,547 shares during the period. Finally, OneDigital Investment Advisors LLC lifted its position in shares of Telomir Pharmaceuticals by 64.3% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 23,000 shares of the company’s stock worth $32,000 after buying an additional 9,000 shares during the last quarter.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.